Meridian Bioscience, Inc. (NASDAQ: VIVO), a Cincinnati, OH-based provider of diagnostic testing solutions and life science raw materials, completed the acquisition of Exalenz Bioscience Ltd., a Modiin, Israel based provider of a urea breath test platform for the detection of Helicobacter pylori.
The amount of the deal was not disclosed.
With the acquisition, Meridian combines its stool antigen tests with Exalenz’s BreathID® urea breath test to provide non-invasive diagnostic assays for a H. pylori active infection.
Led by Jack Kenny, Chief Executive Officer, Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. Through discovery and development, the company provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
FinSMEs
01/05/2020